Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Marchetti

Showing results (81-90 of 128) with videos related to

Pageof 13
Sort By:
Pathologica|August 31, 2021
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS NetworkAntonio Marchetti, Mattia Barbareschi, Massimo Barberis, et al.
Human Mutation|January 2, 2009
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumorsFonnet E Bleeker, Simona Lamba, Sieger Leenstra, et al.
Oncology Letters|February 14, 2018
A multidisciplinary group for prostate cancer management: A single institution experienceAntonella Colasante, Antonietta Augurio, Raffaella Basilico, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2015
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC PatientsAntonio Marchetti, John F Palma, Lara Felicioni, et al.
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapyMichele Milella, Carmen Nuzzo, Emilio Bria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo, Antonio Marchetti, Margaret Skokan, et al.
Oncotarget|March 28, 2020
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of <i>EGFR</i> mutations in NSCLC: a new algorithm for patient selection and personalized treatmentFiamma Buttitta, Lara Felicioni, Alessia Di Lorito, et al.
Molecular Oncology|October 5, 2025
Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarkerAsia Pece, Giulio Lovato, Ilaria Cela, et al.
Critical Reviews in Oncology/Hematology|December 1, 2023
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary groupUmberto Malapelle, Alessandro Delle Donne, Fabio Pagni, et al.
Pageof 13

Showing results (81-90 of 128) with videos related to

Sort By:
Pageof 13
Pathologica|August 31, 2021
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS NetworkAntonio Marchetti, Mattia Barbareschi, Massimo Barberis, et al.
Human Mutation|January 2, 2009
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumorsFonnet E Bleeker, Simona Lamba, Sieger Leenstra, et al.
Oncology Letters|February 14, 2018
A multidisciplinary group for prostate cancer management: A single institution experienceAntonella Colasante, Antonietta Augurio, Raffaella Basilico, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2015
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC PatientsAntonio Marchetti, John F Palma, Lara Felicioni, et al.
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapyMichele Milella, Carmen Nuzzo, Emilio Bria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo, Antonio Marchetti, Margaret Skokan, et al.
Oncotarget|March 28, 2020
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of <i>EGFR</i> mutations in NSCLC: a new algorithm for patient selection and personalized treatmentFiamma Buttitta, Lara Felicioni, Alessia Di Lorito, et al.
Molecular Oncology|October 5, 2025
Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarkerAsia Pece, Giulio Lovato, Ilaria Cela, et al.
Critical Reviews in Oncology/Hematology|December 1, 2023
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary groupUmberto Malapelle, Alessandro Delle Donne, Fabio Pagni, et al.
Pageof 13